Randy D Gascoyne
#100,064
Most Influential Person Now
Researcher
Randy D Gascoyne's AcademicInfluence.com Rankings
Randy D Gascoyneengineering Degrees
Engineering
#2582
World Rank
#3531
Historical Rank
Electrical Engineering
#483
World Rank
#537
Historical Rank
Randy D Gascoynecomputer-science Degrees
Computer Science
#3552
World Rank
#3728
Historical Rank
Computational Linguistics
#202
World Rank
#206
Historical Rank
Machine Learning
#452
World Rank
#458
Historical Rank
Artificial Intelligence
#647
World Rank
#658
Historical Rank
Download Badge
Engineering Computer Science
Randy D Gascoyne's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Randy D Gascoyne Influential?
(Suggest an Edit or Addition)Randy D Gascoyne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Circos: an information aesthetic for comparative genomics. (2009) (7952)
- Revised response criteria for malignant lymphoma. (2007) (4137)
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. (2004) (3681)
- The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. (2002) (2370)
- A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project (1997) (1664)
- Stromal gene signatures in large-B-cell lymphomas. (2008) (1611)
- Frequent mutation of histone modifying genes in non-Hodgkin lymphoma (2011) (1502)
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma (2010) (1436)
- Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. (2004) (1410)
- Oncogenically active MYD88 mutations in human lymphoma (2011) (1341)
- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. (2006) (1256)
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. (2007) (1213)
- Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. (2010) (1140)
- Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma (2018) (1081)
- Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003) (1074)
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways (2008) (971)
- Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. (2005) (965)
- The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. (2003) (948)
- Molecular diagnosis of Burkitt's lymphoma. (2006) (871)
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma (2010) (851)
- Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012) (844)
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma (2008) (828)
- Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin (2010) (780)
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (766)
- EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. (2013) (689)
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. (2014) (682)
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy (2009) (625)
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. (2009) (618)
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. (2008) (612)
- MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. (2013) (606)
- Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. (2006) (605)
- Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases (2002) (586)
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. (2011) (573)
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. (2009) (561)
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers (2011) (554)
- Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. (1999) (537)
- Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. (1997) (526)
- Mantle cell lymphoma: a clinicopathologic study of 80 cases. (1997) (511)
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. (2014) (510)
- Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). (2005) (469)
- Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. (1997) (462)
- Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. (2011) (456)
- Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. (2015) (454)
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. (2015) (434)
- Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
- De novo transcriptome assembly with ABySS (2009) (426)
- Non-Hodgkin lymphoma (2003) (407)
- Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. (2005) (400)
- The tumour microenvironment in B cell lymphomas (2014) (398)
- Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. (2012) (386)
- Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. (2013) (365)
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. (2008) (361)
- Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. (2011) (358)
- SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype (2009) (356)
- Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. (1995) (345)
- Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. (2008) (344)
- Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. (2004) (342)
- Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. (2005) (335)
- Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. (2011) (330)
- Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. (2015) (323)
- Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. (2013) (323)
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. (2012) (322)
- The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development (2015) (321)
- Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. (2004) (317)
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. (2015) (317)
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma (2013) (298)
- Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. (2002) (296)
- Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. (2011) (293)
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. (2010) (288)
- BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. (2004) (284)
- Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (280)
- Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. (2009) (277)
- Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. (2008) (273)
- Cooperative epigenetic modulation by cancer amplicon genes. (2010) (273)
- ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. (2003) (271)
- t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. (1997) (267)
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. (2006) (266)
- CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. (2016) (262)
- EZH2 mutations are frequent and represent an early event in follicular lymphoma. (2013) (261)
- Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. (2013) (245)
- Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. (2007) (243)
- Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. (2007) (240)
- Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. (2007) (233)
- BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. (2006) (231)
- Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. (2006) (229)
- A Multiprotein Supercomplex Controlling Oncogenic Signaling in Lymphoma (2018) (229)
- Loss of signaling via Gα13 in germinal center B cell-derived lymphoma (2014) (226)
- Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. (1995) (225)
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. (2016) (224)
- Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. (2016) (221)
- The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. (2009) (220)
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas (2011) (220)
- Helicobacter pylori and MALT lymphoma. (2005) (214)
- MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. (2012) (213)
- Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy (2003) (209)
- A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. (2006) (207)
- HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species (2010) (200)
- Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma (2007) (200)
- Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma (2007) (199)
- Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells (2016) (198)
- Peripheral T-cell lymphoma. (2011) (197)
- MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. (2003) (197)
- Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. (2011) (197)
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. (2011) (194)
- Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. (1999) (192)
- CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. (2017) (192)
- Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. (2012) (189)
- Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. (2003) (188)
- Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. (2010) (187)
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. (2010) (185)
- The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. (2010) (185)
- Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. (2019) (184)
- Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. (2007) (183)
- Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. (1998) (182)
- Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. (1994) (180)
- The molecular pathogenesis of primary mediastinal large B-cell lymphoma. (2011) (180)
- MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. (2001) (180)
- Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) (2008) (179)
- LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. (2008) (178)
- Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. (2007) (178)
- MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab (2014) (175)
- EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. (2016) (175)
- Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. (2005) (173)
- IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. (2014) (170)
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma (2014) (170)
- BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab (2011) (170)
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. (2006) (169)
- Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18) (2001) (167)
- Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). (1998) (166)
- Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study (2016) (165)
- Transformation of follicular lymphoma to diffuse large B‐cell lymphoma proceeds by distinct oncogenic mechanisms (2007) (165)
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. (2016) (165)
- Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. (2010) (164)
- Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. (2011) (163)
- TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies (2000) (162)
- Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. (2013) (159)
- International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. (2012) (159)
- A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. (2006) (159)
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. (2019) (158)
- Transformation of follicular lymphoma. (2011) (157)
- Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. (2008) (156)
- Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. (2014) (154)
- Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. (2013) (154)
- Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. (2009) (154)
- DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. (2010) (153)
- Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. (2010) (153)
- Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. (2010) (150)
- Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma (2006) (150)
- Prognostic factors in follicular lymphoma. (2010) (150)
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. (2018) (149)
- MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP (2011) (147)
- FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. (2012) (146)
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. (2012) (145)
- Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. (2003) (144)
- Organochlorines and risk of non‐Hodgkin lymphoma (2007) (143)
- Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma (2009) (142)
- The Genetic Basis of Hepatosplenic T-cell Lymphoma. (2017) (140)
- Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. (2001) (139)
- Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. (2010) (139)
- Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. (2016) (138)
- Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens (2015) (137)
- Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. (2009) (137)
- Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas (2004) (136)
- Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomas (2008) (135)
- Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. (2019) (135)
- Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. (1999) (135)
- Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. (2015) (133)
- Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. (2012) (131)
- Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. (1997) (130)
- Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. (2004) (130)
- Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes (2003) (129)
- Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. (2002) (128)
- Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. (2008) (128)
- Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma (2003) (128)
- BCL2 mutations in diffuse large B-cell lymphoma (2012) (127)
- Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. (2014) (125)
- Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. (2013) (124)
- Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. (2009) (124)
- U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. (1997) (123)
- Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. (2019) (123)
- MYC and Aggressive B-cell Lymphomas (2011) (123)
- The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. (2013) (122)
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. (2010) (122)
- The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. (2008) (120)
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. (2013) (119)
- BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. (2010) (119)
- Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. (2013) (117)
- A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2017) (117)
- Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. (2000) (117)
- Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2 (2017) (116)
- Recurrent targets of aberrant somatic hypermutation in lymphoma (2012) (116)
- Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation (1999) (116)
- Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. (2014) (114)
- Per‐channel basis normalization methods for flow cytometry data (2009) (113)
- Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations (2011) (113)
- High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. (2005) (113)
- t(11;18)(q21;q21.1): A recurring translocation in lymphomas of mucosa‐associated lymphoid tissue (malt)? (1992) (111)
- Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. (2002) (111)
- High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy (2011) (111)
- Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. (2006) (110)
- Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. (2007) (110)
- Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. (2015) (110)
- Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. (2005) (109)
- Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia (2016) (107)
- Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. (2007) (107)
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 (2013) (103)
- Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. (2017) (102)
- Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. (2012) (101)
- Limited-stage mantle-cell lymphoma. (2003) (100)
- Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. (2002) (98)
- The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association (2015) (96)
- A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation (2007) (94)
- Pathogenesis of follicular lymphoma. (2012) (94)
- Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease? (2013) (93)
- Cytogenetic abnormalities and clinical correlations in peripheral T‐cell lymphoma (2008) (93)
- Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients (2015) (93)
- Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. (2015) (92)
- Impact of whole genome amplification on analysis of copy number variants (2008) (91)
- Immunolocalization of the ICE/Ced-3–Family Protease, CPP32 (Caspase-3), in Non-Hodgkin's Lymphomas, Chronic Lymphocytic Leukemias, and Reactive Lymph Nodes (1997) (91)
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) (2010) (89)
- Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. (2012) (89)
- Cell of origin of transformed follicular lymphoma. (2015) (88)
- Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity (2013) (87)
- Array-based DNA methylation profiling in follicular lymphoma (2009) (87)
- Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. (2009) (85)
- Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. (1993) (85)
- Long‐term outcomes for patients with limited stage follicular lymphoma (2010) (84)
- New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. (2017) (84)
- Aberrant expression of T-plastin in Sezary cells. (2003) (83)
- ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma (2016) (83)
- Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma (2018) (83)
- Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. (2016) (82)
- ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma (2019) (82)
- Use of the polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma. (1999) (81)
- The whole genome landscape of Burkitt lymphoma subtypes. (2019) (81)
- Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). (2004) (81)
- Role of the tumor microenvironment in mature B-cell lymphoid malignancies (2016) (80)
- The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. (2011) (80)
- CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia (2014) (79)
- TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. (1998) (79)
- Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. (1997) (79)
- Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. (2014) (78)
- Allogeneic haematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma * (2005) (78)
- A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. (2014) (77)
- Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. (1993) (77)
- Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. (2012) (77)
- Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma (2016) (77)
- Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma (2008) (76)
- Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. (2014) (75)
- Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. (2005) (75)
- Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience (1998) (75)
- CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (2007) (74)
- Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma (2007) (74)
- Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3 (1993) (73)
- Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. (2011) (73)
- Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues (2011) (73)
- Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse (2011) (72)
- Mantle cell lymphoma in the ocular adnexal region. (2005) (72)
- MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. (2011) (71)
- Lymphoma stem cells: enough evidence to support their existence? (2010) (70)
- Somatic mutations at EZH 2 Y 641 act dominantly through a mechanism of selectively altered PRC 2 catalytic activity , to increase H 3 K 27 trimethylation (2011) (69)
- The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target (2009) (68)
- Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. (2011) (68)
- Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling (2005) (67)
- Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. (1996) (67)
- Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. (2015) (66)
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma (2021) (66)
- TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. (2012) (66)
- The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases (2004) (66)
- Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. (2007) (64)
- The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. (2009) (64)
- Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment (2015) (62)
- A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. (2012) (62)
- Observation as the initial management strategy in patients with mantle cell lymphoma (2017) (62)
- Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma (2011) (61)
- Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. (2013) (61)
- Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. (2002) (61)
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). (2014) (61)
- The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. (2016) (60)
- Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. (2016) (60)
- Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort (2015) (60)
- A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. (2010) (59)
- Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP (2010) (59)
- Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. (2019) (59)
- Low-grade lymphoma. (2004) (58)
- Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. (2012) (58)
- Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma (2005) (58)
- Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. (2017) (58)
- High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. (2005) (57)
- Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. (2004) (57)
- High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy‐neutral loss of heterozygosity and copy number alterations that target single genes (2010) (57)
- Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma (2013) (57)
- Duodenal follicular lymphoma: Comprehensive gene expression analysis with insights into pathogenesis (2014) (57)
- Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases (2004) (57)
- Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. (1997) (56)
- The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium (2014) (56)
- High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma (2014) (56)
- Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia (2015) (56)
- Prognostic significance of secondary cytogenetic alterations in follicular lymphomas (2008) (56)
- Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma (2000) (56)
- Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era (2017) (55)
- Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. (2002) (55)
- Recurrent genomic rearrangements in primary testicular lymphoma (2015) (55)
- The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era (2012) (55)
- Clinical utility of heteroduplex analysis of TCR gamma gene rearrangements in the diagnosis of T-cell lymphoproliferative disorders. (1997) (54)
- Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma (2015) (54)
- Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis (2005) (54)
- Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation (2004) (53)
- Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. (2017) (53)
- Absence of t(14,18) chromosomal translocation in primary cutaneous B‐cell lymphoma (2002) (53)
- Systemic anaplastic large‐cell lymphoma: Results from the non‐Hodgkin's lymphoma classification project (2001) (52)
- GBV‐C/hepatitis G virus infection and non‐Hodgkin lymphoma: a case control study (2010) (52)
- Vascularization predicts overall survival and risk of transformation in follicular lymphoma (2010) (52)
- Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. (2010) (52)
- Macrophages predict treatment outcome in Hodgkin’s lymphoma (2011) (51)
- Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. (2018) (50)
- CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure (2009) (50)
- Acute leukemia with structural rearrangements of chromosome 3. (1995) (50)
- Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. (2016) (50)
- Can histologic transformation of follicular lymphoma be predicted and prevented? (2017) (50)
- Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases (2002) (49)
- Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
- Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. (2007) (49)
- The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells (2006) (49)
- Bone marrow involvement in T-cell-rich B-cell lymphoma. (1997) (49)
- Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling (2015) (48)
- High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. (2018) (48)
- R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. (2009) (48)
- Atypical lymphoid hyperplasia mimicking lymphoma. (2009) (47)
- Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. (2018) (47)
- Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. (2016) (47)
- Tumor-associated macrophages in diffuse large B-cell lymphoma (2015) (47)
- Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2‐positive germinal center B‐cell lymphomas (2005) (46)
- Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses (2019) (46)
- Multicolour fluorescence in situ hybridization analysis of t(14;18)‐positive follicular lymphoma and correlation with gene expression data and clinical outcome (2003) (46)
- The treatment of primary central nervous system lymphoma in 122 immunocompetent patients (2005) (46)
- AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis (2018) (46)
- Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma (2009) (45)
- Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (2010) (45)
- Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) (2015) (45)
- Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. (2015) (44)
- Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R‐CHOP) (2010) (44)
- Involvement of the X chromosome in non‐Hodgkin lymphoma (2000) (44)
- Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. (2018) (44)
- Hepatitis C infection and B-cell non-Hodgkin's lymphoma in British Columbia: a cross-sectional analysis. (1999) (44)
- Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels (2008) (44)
- Emerging prognostic factors in diffuse large B cell lymphoma (2004) (43)
- Incidence and spectrum of non‐Hodgkin lymphoma in Chinese migrants to British Columbia (2005) (43)
- Limited‐stage diffuse large B‐cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy (2012) (43)
- Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas (2005) (43)
- Genomic profiles of MALT lymphomas: variability across anatomical sites (2011) (43)
- 8q24 translocations in blastic transformation of mantle cell lymphoma. (2000) (43)
- Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. (1999) (43)
- Anaplastic large cell lymphoma: a clinicopathologic analysis (1999) (42)
- Follicular Lymphoma of the Thyroid Gland (2009) (42)
- Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. (1998) (42)
- Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. (2010) (42)
- Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis (2018) (42)
- MYD88 somatic mutations in MALT lymphomas (2012) (42)
- Identification of high‐risk DUSP22‐rearranged ALK‐negative anaplastic large cell lymphoma (2019) (41)
- HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen (2007) (41)
- Histopathologic findings and frequency of clonality detected by the polymerase chain reaction in ocular adnexal lymphoproliferative lesions. (1996) (41)
- Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey. (2004) (40)
- Genetic Variation in H2AFX Contributes to Risk of Non–Hodgkin Lymphoma (2007) (40)
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404) (2014) (40)
- Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium (2017) (40)
- Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. (2017) (40)
- Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus (2002) (39)
- Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma (2016) (39)
- Frequent occurrence of deletions in primary mediastinal B‐cell lymphoma (2007) (39)
- A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. (2018) (39)
- Classification of non-Hodgkin's lymphoma. (2008) (39)
- MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. (2013) (38)
- Multicolor Karyotyping and Clinicopathological Analysis of Three Intravascular Lymphoma Cases (2003) (38)
- A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma (2018) (38)
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma (2019) (38)
- Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. (2012) (38)
- Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B‐cell lymphomas (1999) (37)
- Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. (1997) (37)
- Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. (1996) (37)
- The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. (2016) (36)
- The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2013) (36)
- Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. (1996) (36)
- Characterization of the recurrent translocation t(1;1)(p36.3;q21.1–2) in non‐Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis (2003) (36)
- Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study (2002) (36)
- Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma (2009) (35)
- Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada (2008) (35)
- JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma (2018) (35)
- Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas: A North American PTCL Study Group Project (2014) (34)
- Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. (1995) (34)
- Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6‐megabase region of 6q16–q21 (2004) (34)
- FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. (2014) (34)
- Clinical Significance of the t(14;18) And BCL2 Overexpression in Follicular Large Cell Lymphoma (2000) (32)
- Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. (2010) (32)
- Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). (2015) (32)
- Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 (2016) (32)
- BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. (2014) (32)
- Immunohistochemical analysis of interleukin-1β-converting enzyme/ced-3 family protease, CPP32/Yama/caspase-3, in Hodgkin's disease (1997) (32)
- Model-based clustering of array CGH data (2009) (31)
- Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. (2006) (31)
- Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
- A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
- Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. (2011) (31)
- Frequent association of t(3;14) or variant with other lymphoma‐specific translocations (1995) (30)
- Aggressive B‐cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology (2005) (30)
- Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma. (2007) (30)
- Sequential transcription factor targeting for diffuse large B-cell lymphomas. (2008) (30)
- Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. (1997) (30)
- Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494 (2010) (30)
- Phase II Trial of Bortezomib in Mantle Cell Lymphoma. (2004) (30)
- Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma (2014) (29)
- Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC) (2014) (29)
- TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma (2020) (29)
- Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma (2017) (29)
- Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement (2016) (29)
- Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma * (2006) (29)
- Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. (2018) (29)
- Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non‐Hodgkin's lymphoma (2004) (28)
- Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma (2015) (28)
- Molecular Methods for Detecting t(11;14) Translocations in Mantle‐Cell Lymphomas (1998) (28)
- Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496) (2016) (28)
- MALT Lymphomas. (2001) (28)
- MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma (2021) (27)
- Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). (2006) (27)
- Heavy multinodular cutaneous lymphoid infiltrates: clinicopathologic features and B‐cell clonality (2002) (27)
- Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop (2011) (26)
- Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma (2012) (26)
- Lymphotoxin network pathways shape the tumor microenvironment. (2013) (26)
- Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. (2013) (26)
- CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non‐Hodgkin lymphoma (2012) (26)
- Immunohistochemical Analysis of bc1–2, bax, mcl‐1, and bc1‐X Expression in Ovarian Surface Epithelial Tumors (1998) (25)
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 ) (2014) (25)
- An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. (2015) (25)
- Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells (2015) (25)
- Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study (2008) (25)
- Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component (2011) (25)
- Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. (2020) (24)
- Uncovering novel inter‐ and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique (2002) (24)
- Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types (2015) (24)
- FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. (2018) (24)
- Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal‐binding proteins and show a bi‐activated phenotype (2013) (24)
- Prognostic biomarkers in malignant lymphomas (2010) (24)
- Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma (2017) (23)
- CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial (2012) (23)
- The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas (2010) (23)
- Site of central nervous system (CNS) relapse in patients with diffuse large B‐cell lymphoma (DLBCL) by the CNS‐IPI risk model (2017) (23)
- A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL (2014) (23)
- Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497 (2007) (22)
- Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results (2008) (22)
- A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402 (2015) (21)
- Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. (2007) (21)
- Physical activity, obesity and survival in diffuse large B‐cell and follicular lymphoma cases (2017) (21)
- CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression (2009) (21)
- Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. (2020) (21)
- The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. (2011) (21)
- Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake (2014) (21)
- t(2;5) positive lymphoma with peripheral blood involvement. (1998) (20)
- Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation (2015) (20)
- Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. (1997) (20)
- Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update (2007) (20)
- Low grade gastric MALT Lymphoma: radiographic findings. (2000) (20)
- Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial (2007) (20)
- Hodgkin’s lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments (2006) (20)
- Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. (2013) (20)
- Targeting the microenvironment (2010) (19)
- Outcome of primary cutaneous anaplastic large cell lymphoma: a 20‐year British Columbia Cancer Agency experience (2017) (19)
- Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). (2007) (19)
- Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. (2010) (18)
- Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant (2018) (18)
- Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. (2019) (18)
- The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. (2006) (18)
- Selective ablation of the YxxM motif of IL-7Rα suppresses lymphomagenesis but maintains lymphocyte development (2009) (17)
- EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains (2013) (17)
- Massive bleeding from multiple gastric ulcerations in a patient with lymphocytic gastritis and celiac sprue. (1997) (17)
- Lymphomas with follicular and monocytoid B-cell components. Evidence for a common clonal origin from follicle center cells. (2000) (17)
- Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B) (2010) (17)
- Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma. (2003) (17)
- Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R. (2006) (17)
- Genome‐wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features (2013) (17)
- Cyclin D 3 is a target gene of t ( 6 ; 14 ) ( p 21 . 1 ; q 32 . 3 ) of mature B-cell malignancies (2001) (17)
- A roadmap for discovery and translation in lymphoma. (2015) (17)
- Development of a Biologically Distinct EBV-Related Lymphoproliferative Disorder Following Autologous Bone Marrow Transplantation for an EBV-Negative Post-Renal Allograft Burkitt's Lymphoma (2000) (16)
- Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). (2005) (16)
- Molecular Pathogenesis of Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma (2003) (16)
- T‐cell receptor variable region gene expression in cutaneous T‐cell lymphomas (1992) (16)
- Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab (2019) (15)
- Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing (2019) (15)
- A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). (2014) (15)
- Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay (2017) (15)
- Molecular Signatures of Lymphoma (2004) (15)
- Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia (2013) (15)
- Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
- Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL). (2006) (14)
- Next-generation Sequencing Discoveries in Lymphoma (2013) (14)
- Primary non-Hodgkin's lymphoma and malakoplakia of the vagina: a case report. (1999) (14)
- Clinical, pathological and molecular genetic findings in small intestinal follicle centre cell lymphoma. (1997) (14)
- The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. (2009) (14)
- Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival (2019) (14)
- BCL 2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (2016) (13)
- B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma. (2012) (13)
- XIV. The pathology of transformation of indolent B cell lymphomas (2015) (13)
- The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2014) (13)
- Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD (2018) (13)
- Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma (2008) (13)
- SNP Analysis of Minimally Evolved t(14;18)(q32;q21)-Positive Follicular Lymphomas Reveals a Common Copy-Neutral Loss of Heterozygosity Pattern (2011) (13)
- Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status (2016) (13)
- Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. (2013) (13)
- Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL). (2006) (12)
- Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity (2020) (12)
- Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma (2019) (12)
- ALK-negative Anaplastic Large-cell Lymphoma (ALCL) is Clinically and Immunophenotypically Different from both ALK-positive ALCL and Peripheral T-cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project (2008) (12)
- Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas (2016) (12)
- Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development (2013) (12)
- Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work). (2004) (12)
- Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by:. (2005) (12)
- A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404) (2013) (12)
- Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin. (2009) (11)
- Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. (1997) (11)
- Convergence of risk prediction models in follicular lymphoma (2019) (11)
- A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 (2020) (11)
- Characterization of DLBCL with a PMBL gene expression signature. (2021) (10)
- Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma (2012) (10)
- Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas (2008) (10)
- A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy (2015) (10)
- Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas. (2005) (10)
- Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499 (2017) (10)
- Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment (2010) (10)
- The E 3 ubiquitin ligase UBR 5 is recurrently mutated in mantle cell lymphoma (2013) (10)
- Recommendations for revised response criteria for malignant lymphoma. (2006) (10)
- Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. (2021) (10)
- Cytogenetic findings in reactive lymphoid hyperplasia: Significance of non‐clonal t(3;14) and t(3;22) (2002) (10)
- Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma (2010) (10)
- Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era (2018) (10)
- Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV (2009) (9)
- TBL 1 XR 1 / TP 63 : a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma (2012) (9)
- Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015 (2017) (9)
- Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma (2013) (9)
- The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) (2014) (9)
- CD30 Expression in Diffuse Large B-Cell Lymphoma (2012) (9)
- CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL). (2004) (9)
- Impact of age on genetics and treatment efficacy in follicular lymphoma (2018) (9)
- Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era (2011) (9)
- Bcl-6 and lymphoproliferative disorders. (1997) (9)
- A Pipeline for automated analysis of flow cytometry data: Preliminary results on lymphoma sub-type diagnosis (2009) (9)
- A multiprotein supercomplex controlling oncogenic signalling in lymphoma (2018) (9)
- Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404 (2008) (8)
- Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors (2011) (8)
- The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis (2012) (8)
- Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma (2020) (8)
- Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma (2015) (8)
- Translocation t(3;3)(q21;q26) and thrombocytosis. (1986) (8)
- Establishing the diagnosis of lymphoma: from initial biopsy to clinical staging. (1998) (8)
- A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non‐Hodgkin lymphoma (2007) (8)
- THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL (2017) (8)
- Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma (2016) (8)
- Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. (2009) (8)
- The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era. (2009) (8)
- Parasellar syndrome caused by plasma cell leukemia. (1989) (7)
- Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma (2013) (7)
- HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy. (2009) (7)
- BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. (2020) (7)
- Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma (2020) (7)
- CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression (2014) (7)
- Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). (2016) (7)
- Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
- HTLV-I associated adult T cell leukemia/lymphoma: report of two cases from an Amerindian population in coastal northwest British Columbia. (1996) (7)
- Gene expression signatures in follicular lymphoma: are they ready for the clinic? (2008) (7)
- APPLICATION OF a GENE EXPRESSION‐BASED MODEL IN COMBINATION WITH FDG‐PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033) (2017) (7)
- Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab (2005) (7)
- Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma (DLBCL). (2020) (7)
- Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia. (2012) (7)
- FOXO 1 is a tumor suppressor in classical Hodgkin lymphoma * (2012) (7)
- Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma (2020) (6)
- Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance (2010) (6)
- A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups (2008) (6)
- Clinicopathological analysis of follicular lymphoma with a polyploid karyotype. (1998) (6)
- A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH 2 in lymphomagenesis (2014) (6)
- Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma (2016) (6)
- Predicting survival in follicular lymphoma using tissue microarrays. (2007) (6)
- A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. (2012) (6)
- A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group (2017) (6)
- Faculty Opinions recommendation of ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. (2013) (6)
- The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma. (2006) (6)
- FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP (2010) (6)
- The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL) (2006) (6)
- Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible (2014) (6)
- Biomarkers and prognosis in malignant lymphomas. (2009) (6)
- Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial (2016) (5)
- Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials (2010) (5)
- Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas (2008) (5)
- Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL) (2010) (5)
- Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop (2015) (5)
- Determination of DNA ploidy in archival tissue from non-Hodgkin's lymphoma using flow and image cytometry. (1992) (5)
- Genetic Variation in H 2 AFX Contributes to Risk of Non – Hodgkin Lymphoma (2007) (5)
- Transformed Lymphoma: Incidence and Long-Term Outcome. (2004) (5)
- Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
- Histopathologic, immunophenotypic and genotypic analyses in ocular adnexal lymphoproliferative disorders. (1992) (5)
- Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma (2014) (5)
- EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC). (2016) (5)
- EZH 2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis Short title : EZH 2 epigenetic silencing program in GC B cells (2010) (4)
- Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma (2017) (4)
- Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma. (2007) (4)
- Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma (2008) (4)
- Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections (2010) (4)
- Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404) (2012) (4)
- Controversies in BMT for lymphoma. (2013) (4)
- Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma (2012) (4)
- Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. (2004) (4)
- Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma Lymphoma/Leukemia Molecular Profiling (2007) (4)
- The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo (2008) (4)
- Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies (2019) (4)
- Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era (2013) (4)
- Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics. (2005) (4)
- IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma (2015) (4)
- Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group. (2009) (4)
- LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras. (2007) (4)
- Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. (2021) (4)
- Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas: (2012) (4)
- Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL) (2009) (4)
- Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eatl Oncogenesis (2015) (3)
- HTLV-1: A Significant Retrovirus. (1988) (3)
- Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma (2013) (3)
- Stem cells in Hodgkin lymphoma? (2009) (3)
- Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues (2014) (3)
- Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) (2010) (3)
- BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL (2017) (3)
- Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL). (2004) (3)
- Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma (2015) (3)
- The Science and Value of Lymphoma Classification (2005) (3)
- Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model (2011) (3)
- Prognostic factors in diffuse large B-cell lymphoma (2002) (3)
- Prognostic Indices in Older DLBCL Patients Receiving R-CHOP: An Analysis of the U.S. Intergroup Study (E4494, CALGB 9793). (2006) (3)
- Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. (2005) (3)
- Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study. (2008) (3)
- Molecular heterogeneity of diffuse large B-cell lymphoma. (2004) (3)
- Pathobiology and molecular basis of MALT lymphoma (2008) (3)
- Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. (2016) (3)
- Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C (2013) (3)
- Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (2008) (3)
- Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma. (2006) (3)
- Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy (2015) (3)
- A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma (2016) (3)
- The Architecural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL). (2007) (3)
- Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab (2012) (3)
- CD5-positive diffuse large B-cell lymphoma: a distinct entity? (2002) (2)
- Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population. (2022) (2)
- FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior. (2009) (2)
- Incorporating pathology/biology data into prognostic models in diffuse large B-cell lymphoma (2002) (2)
- Nodular Lymphocyte Predominant Hodgkin Lymphoma and T cell/Histiocyte Rich Large B Cell Lymphoma Endpoints of a Spectrum of one Disease? (2014) (2)
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma (2018) (2)
- TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP (2019) (2)
- Translocations of 11q13 in mantle cell lymphoma fail to disrupt the S mu bp-2 gene. (1997) (2)
- MUTATIONS IN AITL 1 IDH 2 R 172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma (2015) (2)
- Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma (2012) (2)
- Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype (2015) (2)
- Outcome of limited stage nodular lymphocyte predominant Hodgkin lymphoma and the impact of a PET-adapted approach. (2021) (2)
- Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL). (2004) (2)
- Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. (2007) (2)
- General Biomarker Recommendations for Lymphoma. (2016) (2)
- Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. (2012) (2)
- Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST). (2016) (2)
- High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL). (2007) (2)
- The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab. (2009) (2)
- Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project (2005) (2)
- Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE) (2015) (2)
- Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma (2015) (2)
- Retraction. "Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)" (J Clin Pathol 2009;62:128–38;doi:10.1136/jcp.2008.057257). (2012) (2)
- Burkitt's Lymphoma (2011) (2)
- A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial (2011) (2)
- Inactivating Gene Alterations of MHC Class II Transactivator CIITA Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma (2011) (2)
- Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Interleukin 13 and interleukin 13 receptor are frequently expressed by (2013) (2)
- Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways (2016) (2)
- Therapeutic consequences of pathology and prognostic factors in aggressive NHL – Analysis of ALCL (2001) (2)
- Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma (2012) (2)
- Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma (2008) (2)
- Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin’s lymphoma: E1497 final report (2005) (2)
- Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry (2014) (2)
- Cooperative Signaling Through the STAT3 and NF-kB Pathways in Subtypes of Diffuse Large B Cell Lymphoma (2008) (2)
- Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). (2018) (2)
- High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy (2012) (2)
- Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis. (2004) (2)
- Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494 (2007) (2)
- lymphoma mutations are frequent and represent an early event in follicular EZH2 (2013) (1)
- Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status (2014) (1)
- Cell of Origin (COO) of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE) (2017) (1)
- Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma (2013) (1)
- Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. (2007) (1)
- Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm). (2010) (1)
- INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (2019) (1)
- Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia. (1996) (1)
- A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). (2012) (1)
- Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma (2013) (1)
- Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma (2008) (1)
- Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing (2016) (1)
- The outcome of patients with "nodal" peripheral T-cell lymphomas in a complete response following standard chemotherapy. (2014) (1)
- Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma. (2005) (1)
- Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures : a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC / BCL 2 protein coexpression contributes to the inferior survival of (2013) (1)
- The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL (2018) (1)
- Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis (2015) (1)
- Rapid, real-time central pathology review for E1412: A novel and successful paradigm for future National Clinical Trials Network diffuse large B cell lymphoma studies. (2017) (1)
- Scientific category : LYMPHOID NEOPLASIA Title : A new biological prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma (2012) (1)
- High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma (2011) (1)
- Erratum: Long‐term outcomes for patients with limited stage follicular lymphoma (2011) (1)
- MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. (2009) (1)
- A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma. (2009) (1)
- Clinical impact of pathology reviews of outside material: a patient-focused approach. (2011) (1)
- The diversity of p53/p2l transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-Cell lymphoma (DLBCL) (2007) (1)
- ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING (2017) (1)
- Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration. (2006) (1)
- CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma. (2007) (1)
- TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis. (2009) (1)
- Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study (2011) (1)
- International DLBCL Rituximab-CHOP Consortium Program demonstrates high-risk gene expression signatures: a report from The activated B-cell subtype of diffuse large B-cell lymphoma and MYC/BCL2 protein coexpression contributes to the inferior survival of (2013) (1)
- Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome (2011) (1)
- The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas (2013) (1)
- Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. (2014) (1)
- Hypoxia Inducible Factor 1á (HIF-1á) Regulates CD20 Expression in Lymphoma Cells: Possible Implications for Rituximab Based Therapy in Diffuse Large B Cell Lymphoma (DLBCL). (2009) (1)
- Serum Organochlorine Levels and Risk of Non-Hodgkin Lymphoma (2006) (1)
- ANALYSIS OF GENOMIC IMBALANCES AND GENE EXPRESSION CHANGES IN TRANSFORMED FOLLICULAR LYMPHOMA (FL) (2005) (1)
- Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue – An L.L.M.P.P. Project (2013) (1)
- Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496). (2012) (1)
- Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (2016) (1)
- Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas (2011) (1)
- Distinctive Patterns of BCL6 Molecular Alterations in Different Subsets of Diffuse Large B-Cell Lymphoma and Their Functional Consequences. (2005) (1)
- Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level. (2006) (1)
- BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells. (2005) (1)
- Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray (2018) (1)
- BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma (2010) (1)
- Long-term follow up of limited stage primary testicular lymphoma: Outcome and patterns of relapse after combined-modality treatment. (2004) (1)
- Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma. (2006) (1)
- Genomic profiles of MALT lymphomas: variability across anatomic sites Running title: Genomic lesions in MALT lymphomas (2011) (1)
- Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT. (2008) (1)
- DLBCL associated with different clinical outcomes Variability in DNA methylation defines novel epigenetic subgroups of (2014) (1)
- Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC) (2013) (1)
- Expression of p 21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP : A Prospective ECOG and Southwest Oncology Group Correlative Study on E 4494 (2010) (1)
- lymphoma by immunohistochemistry using a tissue microarray Confirmation of the molecular classification of diffuse large B-cell (2013) (1)
- Bone Marow (BM) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Clinical Impact of Discordant Disease. (2006) (1)
- Reply to M. Gleeson et al. (2015) (1)
- FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance (2014) (1)
- Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma (2008) (1)
- Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraf fi n-Embedded Biopsies (2017) (1)
- HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen. (2004) (1)
- DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma (2016) (1)
- Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition (2018) (1)
- The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL) (2010) (1)
- Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis (2011) (1)
- Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP (2010) (1)
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma (2018) (1)
- Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome (2008) (1)
- Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment (2010) (1)
- The use of normosol-R for dilution of red blood cell concentrates prior to transfusion. (1990) (1)
- SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment (2012) (1)
- Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model (2013) (1)
- Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma (2014) (1)
- The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study (2018) (1)
- Pathology and laboratory medicine. (1997) (1)
- Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing (2010) (1)
- DNA copy number gains of TCF4 (E2-2) are associated with poor outcome and the activated B-cell-like subtype of diffuse large B-cell lymphoma (2017) (1)
- B-Cell Lymphomas Sequential Transcription Factor Targeting for Diffuse Large Updated (2008) (1)
- The biology of diffuse large b cell lymphoma (DLBCL) (2014) (1)
- Survival Prediction that Influence Tumor Biology and Improve Gene Expression-Based Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles (2013) (0)
- Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome (2019) (0)
- Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R). (2006) (0)
- Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in Hodgkin’s Lymphoma) in Hematopoiesis (2013) (0)
- Summary and future directions. (2015) (0)
- Faculty Opinions recommendation of Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. (2013) (0)
- MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN‐FIXED, PARAFFIN‐EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT (2017) (0)
- Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy. (2004) (0)
- The outcome of older adults with classic Hodgkin lymphoma in British Columbia (2022) (0)
- High Prevalence of TERT Mutations in Chronic Lymphocytic Leukemia (2008) (0)
- Cancer esearch cular and Cellular Pathobiology uired TNFRSF 14 Mutations in Follicular Lymphoma Are R ociated with Worse Prognosis (2010) (0)
- Management of Hematologic Malignancies: Molecular pathology of lymphoma (2010) (0)
- Paraffin-Embedded Tissues Nuclease Protection Assay on Formalin-Fixed , into Germinal Center and Activated B-Cell Subtypes Using a Accurate Classification of Diffuse Large B-Cell Lymphoma (2011) (0)
- Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy. (2004) (0)
- Predicting Cell Of Origin In Diffuse Large B-Cell Lymphoma By High Dimensional Flow Cytometry (2013) (0)
- Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. (2014) (0)
- Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells (2014) (0)
- The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience (2013) (0)
- recurrent in primary mediastinal large B-cell lymphoma Genomic rearrangements involving programmed death ligands are (2014) (0)
- Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project. (2009) (0)
- Molecular Differences between DTFL and nodal FL 1 Duodenal type and nodal follicular lymphoma differ by their immune microenvironment rather than their mutation profiles Short title : Molecular Differences between DTFL and nodal FL (2018) (0)
- follicular lymphoma Elevated circulating t(14;18) translocation levels prior to diagnosis of (2013) (0)
- Abstract 2445: Integrative genetic analysis identifies therapeutic relevance of cell of origin-specific genetic alterations in diffuse large B-cell lymphoma (2017) (0)
- A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis (2012) (0)
- Frequency of transformation to diffuse large B-cell lymphoma in nodular lymphocyte predominant hodgkin lymphoma: The BCCA Experience (2008) (0)
- number imbalances genomic hybridization reveals prognostically significant DNA copy Genome-wide profiling of follicular lymphoma by array comparative (2013) (0)
- Brief C hemotherapy a nd I nvolved-Region I rradiation f or Limited-Stage D iffuse L arge-Cell L ymphoma: A n 1 8-Year Experience F rom t he B ritish C olumbia C ancer A gency (2002) (0)
- trimethylation of selectively altered PRC2 catalytic activity, to increase H3K27 Somatic mutations at EZH2 Y641 act dominantly through a mechanism (2011) (0)
- The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL) (2017) (0)
- 567 Genomic Analysis of Non-Hodgkin Lymphomas Reveals Mutations in Chromatin Remodelling Genes (2012) (0)
- Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival (2013) (0)
- HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA (2017) (0)
- Faculty Opinions recommendation of CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. (2010) (0)
- Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma (2017) (0)
- Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma (2018) (0)
- Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma (2016) (0)
- Genetic Alterations of the MHC Class II Transactivator CIITA Are Frequent in Primary Mediastinal Large B-Cell Lymphoma and Associated with Diminished MHC Class II Expression (2014) (0)
- B-cell malignancies with a t(14;19)(q32;q13) involving the BCL3 locus predominantly derive from IgVH unmutated precursors (2004) (0)
- analysis compared with classical Hodgkin lymphoma: a matched pair outcome Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma (2014) (0)
- Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach (2022) (0)
- Sulfasalazine inhibits growth of mantle cell lymphoma cell cultures via cyst ine starvation and delays tumour growth in a newly developed murine MCL model (2003) (0)
- Cytokine gene expression and T-cell transcription factor profile of the T-cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma (2007) (0)
- using whole-genome sequencing Mutational and structural analysis of diffuse large B-cell lymphoma (2013) (0)
- Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation (2014) (0)
- Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner (2008) (0)
- Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets (2010) (0)
- Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma (2016) (0)
- 1659PRole of UBR5 mutations in DNA damage response in mantle cell lymphoma (2017) (0)
- Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells. (2012) (0)
- Faculty Opinions recommendation of Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. (2014) (0)
- Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin’s Lymphoma (NHL). (2004) (0)
- survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated (2013) (0)
- T-Cell and B-Cell Non-Hodgkin ’ s Lymphoma Revisited : Therapeutic Paradigms and Advances 1 Introduction (2009) (0)
- Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement (2007) (0)
- Abstract 3941: Recurrent IL4R mutations in primary mediastinal large B cell lymphoma (2015) (0)
- Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers (2017) (0)
- A prospective correlative study of Bcl-6 expression in diffuse, large B-cell lymphoma treated with CHOP or R-CHOP (2006) (0)
- Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target (2016) (0)
- Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma (2008) (0)
- Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study (2016) (0)
- Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens (2016) (0)
- Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma. (2004) (0)
- Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity. (2012) (0)
- David York Mason (1941-2008). Antibody wizard and a founder of modern hemopathology (2008) (0)
- CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma. (2007) (0)
- Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients (2015) (0)
- LOCAS : A new low coverage assembler for short reads (2009) (0)
- Genetic Characterization and Clinical Impact of Loss of MHC Class I and II Expression in De Novo Diffuse Large B-Cell Lymphoma (2017) (0)
- A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas (2015) (0)
- Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. (2008) (0)
- Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma. (2006) (0)
- Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma. (2012) (0)
- Genome-wide miRNAprofiling of mantle cell lymphoma reveals a distinctsubgroup with poor prognosis (2019) (0)
- Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH. (2007) (0)
- Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology (2021) (0)
- Comprar The Lymphoid Neoplasms 3ed | Ama Rohatiner | 9780340809471 | Hodder Arnold (2009) (0)
- Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma (2016) (0)
- Next-Generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation (2012) (0)
- 9. The biology of primary mediastinal large B-cell lymphoma (2016) (0)
- Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. (2019) (0)
- Detection of differential splicing in cancer using gene expression arrays (2011) (0)
- Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis (2016) (0)
- progression and a poorer overall survival identifies a high-risk group of patients with shortened time to disease The presence of TP53 mutation at diagnosis of follicular lymphoma (2013) (0)
- A Single-institution Perspective: The Vancouver Experience with Identification of Clinicopathologic Prognostic Factors (1996) (0)
- AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis (2018) (0)
- Primary mediastinal B-cell lymphoma: The British Columbia experience (2000) (0)
- ‘ ‘ focus on . . . ’ ’ session : primary mediastinal and other extranodal lymphoma (2008) (0)
- Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas (2015) (0)
- The Role of Hepatitis C Virus Infection and Non-Hodgkin Lymphoma in Canada (2006) (0)
- FOXP1 Expression Is a Prognostic Biomarker in Follicular Lymphoma Treated with Immunochemotherapy and Is Associated with Distinct Molecular Features (2017) (0)
- Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma (2010) (0)
- LYMPHOID NEOPLASIA An RCOR1 loss – associated gene expression signature identi fi es a prognostically signi fi cant DLBCL subgroup (2015) (0)
- improve outcome lymphoma similarly to classical Hodgkin lymphoma with ABVD may Treating limited-stage nodular lymphocyte predominant Hodgkin (2011) (0)
- Selective ablation of the YxxM motif of IL-7R alpha suppresses lymphomagenesis but maintains lymphocyte development (38.5) (2009) (0)
- ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures. (2009) (0)
- PATHOLOGIC PROGNOSTIC FACTORS IN DIFFUSE LYMPHOMA AGGRESSIVE NON-HODGKIN'S (1997) (0)
- Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP. (2007) (0)
- subgroups in peripheral T-cell lymphoma Gene expression signatures delineate biological and prognostic (2014) (0)
- cancer cell yibin (2016) (0)
- Treatment and Outcomes of Patients With Limited Stage Primary Cutaneous B-cell Lymphoma (2012) (0)
- ‘ ‘ focus on . . . ’ ’ session : profiling and prognosis (2008) (0)
- Towards the Human Cancer Genome Project: A Sequence-Ready Physical Map of a Follicular Lymphoma Genome. (2005) (0)
- Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (2019) (0)
- LYMPHOID NEOPLASIA Genetic inactivation of TRAF3 in canine and human B-cell lymphoma (2015) (0)
- Histologic Features and Differential Diagnosis of Nodular Lymphocyte Predominance Hodgkin's Lymphoma (NLPHL) (1998) (0)
- High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. (2004) (0)
- FOXO 1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma (2014) (0)
- Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation (2012) (0)
- Abstract A10: MLL2 interactions in follicular and diffuse large B-cell lymphoma (2013) (0)
- CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome (2011) (0)
- Abstract 2945: Characterization of a novel protein-coding gene named TIHL (Translocated in Hodgkin's Lymphoma) (2014) (0)
- Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas (2014) (0)
- Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499 (2015) (0)
- MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL. (2009) (0)
- Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell Lymphoma (2017) (0)
- Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). (2016) (0)
- Distinguishing between immunophenotype and genotype in non-Hodgkin's lymphomas. (2003) (0)
- Reply to L. Wannesson et al (2012) (0)
- Primary Cardiac Lymphoma with Discordant Immunophenotype and Genotype (1999) (0)
- BCL-2 immunoperoxidase staining in follicular lymphoma without t (1994) (0)
- Revealing the Tumor Ecosystem in Follicular Lymphoma By Mass Cytometry (2016) (0)
- Single-Cell Profiling Reveals Distinct Tumor Subtypes and Their Associated T-Cell Environments in Follicular Lymphoma (2018) (0)
- Abstract 2693: Harnessing MALT1 inhibition for rational combinatorial therapy of ABC-DLBCL (2014) (0)
- Sequence analysis De novo transcriptome assembly with ABySS (2009) (0)
- Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma (2013) (0)
- Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. (2016) (0)
- Chapter 4 Molecular Diagnosis of Burkitt lymphoma (2019) (0)
- Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome (2014) (0)
- Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin’s Lymphoma (1997) (0)
- FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION STATUS AND PREDICTS POOR FAILURE‐FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY (2017) (0)
- An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival (2018) (0)
- Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era (2012) (0)
- The Role of UBR5 Mutations in the Pathogenesis of Mantle CELL Lymphoma (2016) (0)
- in the first 100 patients treated in Vancouver primary refractory or relapsed Hodgkin lymphoma: long-term outcome High-dose chemotherapy and autologous stem cell transplantation for (2011) (0)
- Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP (2008) (0)
- UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism (2018) (0)
- Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma (2018) (0)
- Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era (2018) (0)
- High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT). (2009) (0)
- Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience (2014) (0)
- PD2-2-7: Two wrongs make a right: the use of whole genome amplification for pair-wise genome-wide copy number analysis of limited patient material (2007) (0)
- Identification of a Novel Prognostic microRNA Signature in Mantle Cell Lymphoma (2012) (0)
- Implementing a multi-analyte immunohistochemistry panel into a drug development program (2014) (0)
- Plenary Paper (2013) (0)
- Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL) (2015) (0)
- Huntingtin Over-Expression Does Not Alter Overall Survival in Murine Cancer Models (2022) (0)
- Grey-Zone lymphomas: the fear of all lymphoma pathologists (2014) (0)
- t(8;12)(q24;p12) LRMP/MYC (2013) (0)
- AND FLIPI ARE NOT APPLICABLE IN PATIENTS WITH MALT LYMPHOMA (2008) (0)
- FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma (2012) (0)
- Neoplastic hematopathology. Preface. (2009) (0)
- AND FLIPI ARE NOT APPLICABLE IN PATIENTS WITH MALT LYMPHOMA (2008) (0)
- Faculty Opinions recommendation of A tumour suppressor network relying on the polyamine-hypusine axis. (2012) (0)
- Brief report The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival (2008) (0)
- ALCOHOL INTAKE AND RISK OF NON-HODGKIN LYMPHOMAS IN THE PROSPECTIVE NIH-AARP DIET (2017) (0)
- Insights Into Pathophysiology of Lymphomas Help Identify Therapeutic Targets (2014) (0)
- The Molecular Pathogenesis of Follicular Lymphoma (2012) (0)
- Genome‐wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas (2014) (0)
- IPI24 supplemental material submitted (2015) (0)
- Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma (2019) (0)
- Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL). (2009) (0)
- Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma (2015) (0)
- Running title miRNA profiling of tonsilar lymphocytes and DLBCL Authors (2008) (0)
- CD56+ Monomorphic Enteropathy-Type T-Cell Lymphoma Is a Genetically Distinct Entity Characterized by 8q Gains and Lack of 1q and 5q Gains. (2005) (0)
- Treatment and Outcomes in Patients With Primary Cutaneous B-Cell Lymphoma: The BC Cancer Agency (2013) (0)
- diffuse large B-cell lymphoma treated in the rituximab era An enhanced International Prognostic Index (NCCN-IPI) for patients with (2014) (0)
- LYMPHOID NEOPLASIA Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas (2016) (0)
- What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma (2011) (0)
- Lymphoma genomics: how might next generation sequencing penetrate laboratory practice? (2014) (0)
- FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3′ UTR MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA (2019) (0)
- Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL. (2015) (0)
- Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations. (2009) (0)
- Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL). (2007) (0)
- Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP. (2007) (0)
- Chromosomal aberrations in gray zone lymphomas (2011) (0)
- Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mant (2011) (0)
- Original t(ll;18)(q21;q21) is the most common translocation in MALT lymphomas (2005) (0)
- Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study (2015) (0)
- Abstract 3480:TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma (2019) (0)
- University of Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (0)
- 9202 Long-term outcomes for patients with limited stage, follicular lymphoma: involved regional radiotherapy versus involved nodal radiotherapy (2009) (0)
- A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408 (2018) (0)
- Abstract 3765: Somatic JAK-STAT mutations in subtypes of aggressive B-cell lymphomas with DLBCL morphology (2019) (0)
- Sun Exposure and the Risk of Non-Hodgkin Lymphoma by Ethnicity (2006) (0)
- Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas (2015) (0)
- Hodgkin lymphoma: from discovery to clinical translation (2014) (0)
- ‘ ‘ focus on . . . ’ ’ session : transformation 086 SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION (2008) (0)
- Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality. (2006) (0)
- Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma. (2009) (0)
- The diversity of p53/p21 transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-cell lymphoma (DLBCL) (2007) (0)
- Abstract 959: FAS mutations induce therapeutic resistance in non-Hodgkin lymphomas (2014) (0)
- Faculty Opinions recommendation of Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. (2012) (0)
- Hetewduplex Analysis of TCR Gamma Gene Rearrangements (2015) (0)
- transformation lymphoma are associated with both overall survival and risk of Regions of acquired uniparental disomy at diagnosis of follicular (2013) (0)
- Predictor of survival Diffuse large B-cell lymphoma (2009) (0)
- Lymphoma: Current concepts and difficult diagnostic disorders (2004) (0)
- in mantle cell lymphoma mutations NOTCH1 Whole transcriptome sequencing reveals recurrent (2012) (0)
- subtype-specific lesions with an impact on the clinical outcome Genome-wide DNA profiling of marginal zone lymphomas identifies (2011) (0)
- Short Communication Immunohistochemical Analysis of Mci-1 and Bcl-2 Proteins in Normal and Neoplastic Lymph Nodes (2007) (0)
- chemotherapy diffuse large B-cell lymphoma patients treated with R-CHOP MYC gene rearrangements are associated with a poor prognosis in (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Randy D Gascoyne?
Randy D Gascoyne is affiliated with the following schools:
